Critical appraisal:Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al 2011

From Cancer Guidelines Wiki

Critical Appraisal

Article being appraised

Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011 Jul;100(1):76-85 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21757247.


Applicable clinical question

Key Facts

Study Design

randomised controlled trial

Number of Patients:

42


Includes an economic evaluation

no

Evidence ratings

Level of evidence

II

Risk of bias
Low risk of bias Comments: Larger study including patients with stage I-III disease, only 10% with stage I. Subset analysis suggested increasing local control with increasing stage in patients assigned to investigatioanl treatment.


Size of effect
3 Reason for decision: No benefit with intervention
Relevance of evidence
1 Additional comments: Primary outcome is survival.
Result of appraisal

Jutta's tick icon.png Included




Completed by

Professor David Ball MB BS, MD, FRANCZR


Jutta's tick icon.png This appraisal has been completed.


Article
Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011 Jul;100(1):76-85 Available from: http://www.ncbi.nlm.nih.gov/pubmed/21757247.
Assigned to
User:David.ball
Topic area
Guidelines:Lung cancer/Treatment/Non-small-cell stage I inoperable
Clinical question
Form
Form:Critical appraisal


Section below only relevant for Cancer Council Project Officer

Edit appraisal assignment